Compare Sanofi SA (SNY) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs ProShares UltraPro S&P500 — how do they compare? Sanofi SA trades at $43.7 (market cap $104.83B), while ProShares UltraPro S&P500 trades at $139.72. The key difference: Sanofi SA pays a 5.5% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | UPRO | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $150.93 |
52-Week Low | $41.33 | $89.29 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
UPRO trades at $138.50, down 0.4% on the day, with a bearish technical signal driven by moving averages. Key support lies at $135, while resistance is at $141. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights S&P 500 concentration risks and AI-driven market volatility, influencing this leveraged ETF's performance.
The outlook is cautious due to technical weakness and broader market concerns over valuation and tech stock reliance. Risks include market corrections and ETF-specific volatility. Investors should weigh the lack of fundamental data against the leveraged exposure to S&P 500 trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
